Zobrazeno 1 - 10
of 369
pro vyhledávání: '"Peter Schmid"'
Autor:
Hope Rugo, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, Patricia Gómez Pardo, Komal Jhaveri, Monica Motwani, Oh Kyu Yoon, Hao Wang, Wendy Verret, Sara Tolaney
Publikováno v:
Cancer Research. 83:GS1-11
Background: HR+/HER2– mBC, the most common subset of breast cancer, is treated with sequential endocrine therapy + targeted agents followed by sequential single-agent chemotherapy (CT), with increasingly shorter benefit duration with each subsequen
Autor:
Frederik Marmé, Aditya Bardia, Hope Rugo, Peter Schmid, Sara M. Tolaney, Mafalda Oliveira, Andreas Schneeweiss, Ling Shi, Wendy Verret, Mahdi Gharaibeh, Anju Shah, Javier Cortés
Publikováno v:
Cancer Research. 83:P4-07
Background: For HR+/HER2- metastatic breast cancer (MBC) patients, after resistance to endocrine therapy (ET), treatment options are mostly limited to traditional chemotherapies (CT) that offer poor survival and quality of life (QoL), creating an are
Autor:
Patrick Neven, Nicole Stahl, Maria Vidal, Miguel Martín, Nadia Harbeck, Peter A. Kaufman, Francois-Clement Bidard, Peter A. Fasching, Philippe Aftimos, Erika Hamilton, Stacey Carter, Peter Schmid, Duncan Wheatley, Manali Bhave, Kelly K. Hunt, Swati A. Kulkarni, Roohi Ismail-Khan, Claudia Karacsonyi, Shawn T. Estrem, Umut Ozbek, Bastien Nguyen, Eva Ciruelos
Publikováno v:
Cancer Research. 83:P6-10
Background: Imlunestrant is a novel, orally bioavailable selective estrogen receptor degrader (SERD) with pure antagonistic properties that result in sustained inhibition of estrogen receptor (ER)-dependent gene transcription and cell growth. In a ph
Autor:
Sara Tolaney, Peter Schmid, Aditya Bardia, Frederik Marmé, Delphine Loirat, Priyanka Sharma, Hao Wang, Olivia Fu, Wendy Verret, Hope Rugo
Publikováno v:
Cancer Research. 83:P3-07
Background: SG is a Trop-2-directed antibody-drug conjugate approved by the FDA for patients (pts) with metastatic triple-negative breast cancer who received ≥2 prior chemotherapies (≥1 for MBC). In the phase 3 TROPiCS-02 study, SG demonstrated a
Autor:
Alejandro Martinez Chibly, Alice Shia, Radia Johnson, Michael S. Hwang, Marc Hafner, Ciara Metcalfe, Kalpit Shah, Michal Slyper, Chris Bolen, Sarah E. Pinder, Alastair M. Thompson, Steven Gendreau, Peter Schmid
Publikováno v:
Cancer Research. 83:PD10-06
Background: Endocrine therapy (ET) is the mainstay of ER+ BC treatment. However; up to 20% of ER+ BC tumors progress into metastatic disease and develop ET resistance, underscoring the need for combination therapies. Preclinical data suggest that com
Autor:
Rebecca Dent, David W. Cescon, Thomas Bachelot, Kyung Hae Jung, Zhi-Ming Shao, Shigehira Saji, Tiffany A. Traina, Petra Vuković, Darlington Mapiye, Micah Maxwell, Peter Schmid, Javier Cortés
Publikováno v:
Cancer Research. 83:OT1-03
Introduction: Despite recent treatment advances, the prognosis for patients diagnosed with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) remains poor. Single-agent chemotherapy has been the mainstay of treatment for
Autor:
Mattea Reinisch, Simona Bruzas, Oleg Gluz, Beyhan Ataseven, Peter Schmid, Javier Cortés, Jens‐Uwe Blohmer, Satyendra Shenoy, Mark H. Dyson, Christine Dittmer‐Grabowski, Ouafaa Chiari, Hakima Harrach, Daniel Gebauer, Alexander Traut, Sherko Kuemmel
Publikováno v:
Scientia
Adjuvant chemotherapy; Early breast cancer; Lymph node-positive Quimioterapia adyuvante; Cáncer de mama temprano; Ganglio linfático positivo Quimioteràpia adjuvant; Càncer de mama precoç; Gangli limfàtic positiu The utility of multigene express
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c681926851bcc6c69d8713c7a7499fe7
https://hdl.handle.net/11351/9976
https://hdl.handle.net/11351/9976
Autor:
Sherene Loi, Roberto Salgado, Peter Schmid, Javier Cortes, David W. Cescon, Eric P. Winer, Deborah L. Toppmeyer, Hope S. Rugo, Michelino De Laurentiis, Rita Nanda, Hiroji Iwata, Ahmad Awada, Antoinette R. Tan, Yuan Sun, Vassiliki Karantza, Anran Wang, Lingkang Huang, Assieh Saadatpour, Razvan Cristescu, Jennifer Yearley, Jared Lunceford, Petar Jelinic, Sylvia Adams
Publikováno v:
JCO Precision Oncology.
PURPOSE In the two-cohort phase II KEYNOTE-086 study (ClinicalTrials.gov identifier: NCT02447003 ), first-line and second-line or later pembrolizumab monotherapy demonstrated antitumor activity in metastatic triple-negative breast cancer (mTNBC; N =
Autor:
Ailsa J. Oswald, Stefan N. Symeonides, Duncan Wheatley, Stephen Chan, Adrian Murray Brunt, Karen McAdam, Peter Schmid, Simon Waters, Christopher Poole, Chris Twelves, Timothy Perren, John Bartlett, Tammy Piper, Eve Macdonald Chisholm, Michelle Welsh, Robert Hill, Lisa E. M. Hopcroft, Peter Barrett-Lee, David A. Cameron
Publikováno v:
Oswald, A, Symeonides, S N, Wheatley, D, Chan, S, Murray Brunt, A, McAdam, K, Schmid, P, Waters, S, Poole, C, Twelves, C, Perren, T, Bartlett, J, Piper, T, Macdonald Chisholm, E, Welsh, M, Hill, R, Hopcroft, L E, Barrett-Lee, P & Cameron, D A 2023, ' ARomatase Inhibition plus/minus Src-inhibitor SaracaTinib (AZD0530) in Advanced breast CAncer Therapy (ARISTACAT): a randomised phase II study ', Breast cancer research and treatment . https://doi.org/10.1007/s10549-023-06873-8
Purpose The development of oestrogen resistance is a major challenge in managing hormone-sensitive metastatic breast cancer. Saracatinib (AZD0530), an oral Src kinase inhibitor, prevents oestrogen resistance in animal models and reduces osteoclast ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05748b6217c9d05f9fb0f6d40ba51272
https://hdl.handle.net/20.500.11820/9d500f76-cfbe-46d5-b5fc-dbc14bfd8050
https://hdl.handle.net/20.500.11820/9d500f76-cfbe-46d5-b5fc-dbc14bfd8050
Autor:
Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, Florence Dalenc, Miguel J Gil Gil, Manuel Ruiz Borrego, Joaquín Gavilá, Miguel Sampayo-Cordero, Elena Aguirre, Peter Schmid, Frederik Marmé, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez-De Dueñas, Vicente Carañana, Kepa Amillano, Leonardo Mina, Andrea Malfettone, Javier Cortés, Antonio Llombart-Cussac
Publikováno v:
Scientia
Background Palbociclib has gained a central role in the treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC). Despite its manageable toxicity profile, venous thromboembo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e94856ca3e331564bbf534f081808407
https://academic.oup.com/oncolo/article-pdf/28/1/23/48837357/oyac205.pdf
https://academic.oup.com/oncolo/article-pdf/28/1/23/48837357/oyac205.pdf